Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony P Ford

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
European Urology|July 13, 2004
P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxinCiaran M Brady, Apostolos Apostolidis, Yiangos Yiangou, et al.
Acta Neuropathologica Communications|June 7, 2014
Adenosine triphosphate drives head and neck cancer pain through P2X2/3 heterotrimersYi Ye, Kentaro Ono, Daniel G Bernabé, et al.
The European Respiratory Journal|February 8, 2020
Author response: The human cough reflex has separate, distinct pathwaysAlyn H Morice, Michael M Kitt, Anthony P Ford, et al.
The European Respiratory Journal|April 27, 2019
The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled studyAlyn H Morice, Michael M Kitt, Anthony P Ford, et al.
British Journal of Pharmacology|March 22, 2005
Antagonism of ATP responses at P2X receptor subtypes by the pH indicator dye, Phenol redBrian F King, Min Liu, Andrea Townsend-Nicholson, et al.
The European Respiratory Journal|January 18, 2020
Gefapixant in two randomised dose-escalation studies in chronic coughJaclyn A Smith, Michael M Kitt, Peter Butera, et al.
Journal of Clinical Pharmacology|April 23, 2024
Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy AdultsJesse C Nussbaum, Azher Hussain, Peter Butera, et al.
The Lancet. Respiratory Medicine|February 29, 2020
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trialJaclyn A Smith, Michael M Kitt, Alyn H Morice, et al.
Nature Medicine|September 6, 2016
Purinergic receptors in the carotid body as a new drug target for controlling hypertensionWioletta Pijacka, Davi J A Moraes, Laura E K Ratcliffe, et al.
The Journal of Allergy and Clinical Immunology|January 22, 2016
Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphateSara J Bonvini, Mark A Birrell, Megan S Grace, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
European Urology|July 13, 2004
P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxinCiaran M Brady, Apostolos Apostolidis, Yiangos Yiangou, et al.
Acta Neuropathologica Communications|June 7, 2014
Adenosine triphosphate drives head and neck cancer pain through P2X2/3 heterotrimersYi Ye, Kentaro Ono, Daniel G Bernabé, et al.
The European Respiratory Journal|February 8, 2020
Author response: The human cough reflex has separate, distinct pathwaysAlyn H Morice, Michael M Kitt, Anthony P Ford, et al.
The European Respiratory Journal|April 27, 2019
The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled studyAlyn H Morice, Michael M Kitt, Anthony P Ford, et al.
British Journal of Pharmacology|March 22, 2005
Antagonism of ATP responses at P2X receptor subtypes by the pH indicator dye, Phenol redBrian F King, Min Liu, Andrea Townsend-Nicholson, et al.
The European Respiratory Journal|January 18, 2020
Gefapixant in two randomised dose-escalation studies in chronic coughJaclyn A Smith, Michael M Kitt, Peter Butera, et al.
Journal of Clinical Pharmacology|April 23, 2024
Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy AdultsJesse C Nussbaum, Azher Hussain, Peter Butera, et al.
The Lancet. Respiratory Medicine|February 29, 2020
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trialJaclyn A Smith, Michael M Kitt, Alyn H Morice, et al.
Nature Medicine|September 6, 2016
Purinergic receptors in the carotid body as a new drug target for controlling hypertensionWioletta Pijacka, Davi J A Moraes, Laura E K Ratcliffe, et al.
The Journal of Allergy and Clinical Immunology|January 22, 2016
Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphateSara J Bonvini, Mark A Birrell, Megan S Grace, et al.
Pageof 4